Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: An observational cohort

Antiviral Therapy

Volumn 21, Issue 7, 2016, Pages 611-619

  André Garnier, Elisabeth ^a   Ribeyrol, Olivier ^a   Gournay, Jerome ^a   Besse, Bernard ^a   Coste Burel, Marianne ^a   Mabille Archambeaud, Isabelle ^a   Billaud, Eric ^a   Biron, Charlotte ^a   Pineau, Solene ^a   Raffi, François ^a   Imbert Marcille, Berthe Marie ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC VARIATION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; MILD FIBROSIS; MIXED INFECTION; NONHUMAN; NONSTRUCTURAL PROTEIN 3 GENE; NONSTRUCTURAL PROTEIN 5A GENE; NONSTRUCTURAL PROTEIN 5B GENE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RELAPSE; SUSTAINED VIRAL RESPONSE; THROMBOCYTOPENIA; VIROLOGICAL FAILURE; VIRUS LOAD; VIRUS RESISTANCE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; GENETICS; MUTATION; TREATMENT FAILURE; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; MUTATION; SOFOSBUVIR; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85006117348     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3053     Document Type: Article

References (27)

1. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58:428-438.
2. Hézode C, Bronowicki J-P. Ideal oral combinations to eradicate HCV. The role of ribavirin. J Hepatol 2016; 64:215-225.
3. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
4. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765.
5. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
6. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64:486-504.
7. Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 2015; 62:286-293.
8. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille B-M, André-Garnier E. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 2012; 185:94-100.
9. Sandres-Sauné K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 2003; 109:187-193.
10. Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39:1363-1375.
11. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12:405-413.
12. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63:199-236.
13. AFEF. French Association Study of Liver. (Updated 1 February 2016. Accessed 1 March 2016.) Available from http://www.afef.asso.fr/communication/afef/index.phtml
14. Hilgenfeldt EG, Schlachterman A, Firpi RJ, Hepatitis C. Treatment of difficult to treat patients. World J Hepatol 2015; 7:1953-1963.
15. Plançon M, Besse B, Gournay J, et al. [Anti HCV tritherapy: experience over a year and genotyping interest]. Médecine Mal Inféctieuses 2013; 43:56. French.
16. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase III study. Hepatology 2015; 61:1127-1135.
17. Infectious Diseases Society of America. Retreatment of persons in whom prior therapy has failed. (Updated 1 October 2015. Accessed 1 December 2015.) Available from http://www.hcvguidelines.org/full-report/retreatment-persons-whom-prior-therapy-has-failed
18. Nicolini LA, Menzaghi B, Ricci E, et al. Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? Eur J Gastroenterol Hepatol 2016; 28:37-41.
19. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56:3359-3368.
20. Aloia AL, Locarnini S, Beard MR. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther 2012; 17 6 Pt B:1147-1162.
21. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61:56-65.
22. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in Phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59:1666-1674.
23. Pawlotsky J-M. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology 2015; 148:468-479.
24. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-3650.
25. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58:902-911.
26. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58:646-654.
27. Cento V, Chevaliez S, Perno CF. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS. 2015; 10:381-389.